Email this article Changes in CD19 expression after blinatumomab treatment in pediatric patients with relapsed/refractory B-lineage acute lymphoblastic leukemia
- Authors: Gluhanyuk E.V.1, Illarionova O.I.1, Kashpor S.A.1, Plyasunova S.A.1, Miakova N.V.1, Maschan A.A.1, Popov A.M.1
-
Affiliations:
- Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
- Issue: Vol 16, No 4 (2017)
- Pages: 21-26
- Section: Статьи
- Submitted: 09.08.2018
- Published: 09.11.2017
- URL: https://hemoncim.com/jour/article/view/4
- DOI: https://doi.org/10.24287/1726-1708-2017-16-4-21-26
- ID: 4
Cite item
Full Text
Abstract
Blinatumomab is a bispecific T-cell engager (BiTE) antibody construct targeting CD3 and CD19, resulting in T-cell-mediated lysis of malignant B cells. CD19 downexpression is shown to be one of the possible mechanisms of tumor cells adaptation and subsequent escape from treatment. The aim of the present study was to evaluate changes of CD19 expression on residual tumor cells in children with BCP-ALL treated with blinatumomab. 39 patients with relapsed/refractory BCP-ALL who completed at least one course of blinatumomab, were studied. MRD monitoring was performed by 8-color flow cytometry. In those children, who didn’t respond and/or developed subsequent relapse, CD19 downexpression seems to be one of the significant pathways for tumor escape from blinatumomab – 50% of relapses were CD19-negative, and in 26.3% of all relapsed/resistant cases CD19-negative blasts were detected at least on MRD level. Rather frequent loss of CD19 could be a serious obstacle for flow cytometric MRD monitoring, but application of expanded antibodies panel and use of 10–12-color investigation allows residual blasts detection in nearly all cases.
About the authors
E. V. Gluhanyuk
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0003-2921-9770
Russia 117997, Moscow, Samory Mashela st., 1 Russian Federation
O. I. Illarionova
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, ImmunologyRussia 117997, Moscow, Samory Mashela st., 1 Russian Federation
S. A. Kashpor
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, ImmunologyRussia 117997, Moscow, Samory Mashela st., 1 Russian Federation
S. A. Plyasunova
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, ImmunologyRussia 117997, Moscow, Samory Mashela st., 1 Russian Federation
N. V. Miakova
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0002-4779-1896
Russia 117997, Moscow, Samory Mashela st., 1 Russian Federation
A. A. Maschan
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
ORCID iD: 0000-0002-0016-6698
Russia 117997, Moscow, Samory Mashela st., 1 Russian Federation
A. M. Popov
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
Author for correspondence.
Email: uralcytometry@gmail.com
ORCID iD: 0000-0002-0889-6986
MD, PhD, Head of Cell immunology and immunogenesis laboratory
Russia 117997, Moscow, Samory Mashela st., 1
+7 (495) 287-6570
Russian FederationReferences
Supplementary files
